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HPV6 oncoproteins target a number of PDZ domain-containing substrates for
proteasome mediated degradation. One of these, Discs Large (Dlg), is involved in the regulation of cell
polarity and proliferation control. Previous studies had suggested that Dlg when hyperphosphorylated by
osmotic shock, or when present in the nucleus could be preferentially targeted by E6. In this study we use
phospho-speciﬁc antibodies directed against Dlg phosphorylated at residues S158 and S442 to show that
these two observations are, in fact, linked. Dlg, when phosphorylated on S158 and S442 by CDK1 or CDK2,
shows a preferential nuclear accumulation. However, these forms of Dlg are absent in cells derived from HPV-
induced cervical cancers. Upon either proteasome inhibition or siRNA ablation of E6 expression, we see
speciﬁc rescue of these phosphorylated forms of Dlg. These results demonstrate that nuclear forms of Dlg
phosphorylated on its CDK phospho-acceptor sites has enhanced susceptibility to E6-induced degradation
and place previous studies on the stress-induced phosphorylation of Dlg into a relevant biological context.
© 2009 Elsevier Inc. All rights reserved.IntroductionPerhaps the most well-documented role of the human Discs Large
Tumour Suppressor hDlg in cancer is its role in Human Papillomavirus
(HPV)-mediated cervical cancers. Human Papillomaviruses are small
double stranded DNA viruses which cause a plethora of neoplastic
diseases of the epithelia, stretching from benign warts to lethal
carcinomas. Cervical cancer caused by HPV is the second major cause of
cancer-related death in women worldwide (Parkin, 2006), and HPV
infection has been detected in virtually 100% of all cervical cancer cases.
Only a small subset of the many HPV types known is associated with the
actual development of cancer (deVilliers,1994) andHPVs are accordingly
classiﬁed into high-risk or low-risk types. The high-risk mucosal HPV E6
proteins are unique in possessing a PDZ domain-binding motif (PBM) at
their extreme carboxyl-termini (Kiyono et al.,1997; Lee et al.,1997)which
isnot involved inp53binding anddegradation (Pimet al.,1994). hDlgwas
the ﬁrst PDZ-protein substrate shown to bind the C-terminal PBMs of
high-risk HPV-16 and HPV-18 E6 proteins (Kiyono et al., 1997; Lee et al.,
1997). Post binding, E6 targets Dlg for ubiquitin mediated degradation
(Gardiol et al.,1999). At this stage it is impossible to state deﬁnitively how
critical the Dlg interaction is for HPV-inducedmalignancy, although there
is compelling evidence that suggests a role in malignancy. Transgenic
mice expressing an E6 lacking the PBM, fail to showepithelial hyperplasia
(Nguyen et al., 2003). This E6 does not contribute to the promotional
stagesof skincarcinogenesis in this system, although it retains its ability to
contribute toprogression (Simonson et al., 2005). These studies obviouslyll rights reserved.point to a vital role for the PDZ binding motif. Analysis of Dlg in
histological specimens from patients with HPV-positive invasive carci-
nomas showednotonlyamarked reduction inDlg levels, but alsomassive
alterations in localisation of the protein in cells and tissues as the lesions
developed (Watson et al., 2002; Cavatorta et al., 2004). This points
towards the importance of the localisation of hDlg in HPV-mediated
cancers and its potential importance in preventing the progression of the
disease. Phosphorylation of hDlg has been shown to be an important
event in the context of its degradation by HPV E6, where MAPK
phosphorylation of hDlg upon osmotic shock makes it more susceptible
to E6-mediated degradation (Massimi et al., 2006). Recently we have
found that hDlg is differentially phosphorylated during the cell cycle by
cdk1 and cdk2. This phosphorylation of hDlg by the CDKs on serines 158
and 442 changes its pattern of localisation to a predominantly nuclear
one, and makes it more stable and less susceptible to ubiquitination
(Narayan et al., 2008). In this study, we use phospho-speciﬁc antibodies
against phospho-S158 and phospho-S442 to investigate the pattern of
hDlg expression in high-risk HPV-containing cell lines HeLa and CaSki, in
comparison with HPV-negative HaCaT cells, to understand the effect of
these phosphorylation events on hDlg in connection with its interaction
with, and manipulation by, the HPV E6 oncoprotein.
Results
hDlg phosphorylated on Serine 158 and Serine 442 is predominantly
nuclear
Having shown previously that hDlg, when doubly mutated at S158
and S442, had an altered pattern of expression in transient
Fig. 1. Nuclear fractionation of HaCaT cells highlights phosphorylated serine 158 and
serine 442 primarily in the nucleus. HaCaTcells were plated on 10 cm culture dishes and
grown overnight in DMEM supplemented with 10% fetal bovine serum, penicillin–
streptomycin (100 U/ml) and glutamine (300 μg/ml). The cells were fractionated into
the cytoplasmic and nuclear fractions according to the manufacturer's instructions,
using the NE-PER Nuclear and Cytoplasmic Extraction Reagents from Pierce Biotechnol-
ogy (# 78833) and subjected to western blotting. The blots were probed with the anti-
Dlg polyclonal rabbit antibody (Santacruz) and the anti-phospho-serine 158 and 442
antibodies. P84, a nuclear matrix marker (Abcam) and α-tubulin (Sigma) serve as
controls for the nuclear and cytoplasmic fractions respectively.
2 Rapid Communicationtransfection experiments (Narayan et al., 2008), we ﬁrst wanted to
investigate directly where hDlg was predominantly expressed when
phosphorylated on these two sites. To do this, we decided to use the
phospho-speciﬁc antibodies in combination with a biochemical
fractionation assay. HaCaT cells were plated on 10 cm culture dishes
and grown overnight. The cells were then washed extensively in PBS
and fractionated into the nuclear and cytoplasmic fractions. The
extracts were then resolved by SDS-PAGE and subjected to western
blotting. The integrity of the differential extraction procedure was
veriﬁed by using the speciﬁc nuclear and cytoplasmic markers p84 (a
nuclear matrix protein marker) and α-tubulin, respectively. As can be
seen from Fig. 1, hDlg is detected in approximately equal amounts inFig. 2. The nuclear form of hDlg is preferentially degraded by HPV 18 and 16 E6. (a) CaSk
fractionation as described in Fig. 1 for HaCaT cells. The fractions were subjected to western
performed with (b) HaCaT cells, (c) CaSki cells and (d) HeLa cells with or without the proteaboth the nuclear and cytoplasmic extracts with the rabbit polyclonal
anti-hDlg antibody. In contrast, the anti phospho-speciﬁc antibodies
against serine 158 and serine 442 detect hDlg mainly in the nuclear
fraction, demonstrating that hDlg is predominantly nuclear when
phosphorylated on either or both of these sites. There is also a weak
phosphorylation detectable on S158 in the cytoplasmic fraction, most
likely reﬂecting phosphorylation of this residue by kinases other than
CDKs (Massimi et al., 2006; Narayan et al., 2008).
HPV18 E6 and HPV16 E6 preferentially target phosphorylated nuclear
forms of hDlg for proteasome mediated degradation
Previous studies (Massimi et al., 2004, 2006) have shown that
nuclear formsof hDlg are preferentially degradedbyHPVE6. In addition,
certain phosphorylation events induced by the JNK and p38 kinases
enhance E6 mediated degradation; some of these phosphorylation
events can occur on serine 158 and serine 442 (Sabio et al., 2005).
However, in the context of CDK regulation, only S158 and S442 are
substrates (Narayan et al., 2008). Therefore we were obviously
interested in investigating whether the enhanced targeting of phos-
phorylated and nuclear forms of hDlg by E6 is in any way linked. To
address this question, we performed a similar fractionation experiment
to that described above, this time analysing the HPV16-positive cell line
CaSKi and the HPV18-positive cell line HeLa. Fig. 2a clearly shows
approximately equal amounts of hDlg protein in both nuclear and
cytoplasmic fractions in HaCaT cells. In contrast, both CaSKi and HeLa
cells have virtually nohDlgpresent in thenuclear fraction,whilst there is
readily detected cytoplasmic hDlg inCaSki cells. It is known thathDlg is a
better target forHPV-18E6 (Thomas et al., 2001) than forHPV-16E6 and
this is reﬂected in the lower levels of hDlg protein seen inHeLa cells (Fig.
2a), although HeLa cells also have greatly reduced levels of hDlgi and HeLa cells were grown and plated onto 10 cm dishes and subjected to nuclear
blotting and the blots probed with an anti-hDlg antibody. Similar experiments were
some inhibitor MG-132. p53 is used as a control for the rescue of protein with MG-132.
3Rapid Communicationtranscription, which in turn also contributes to the overall lower level of
hDlg protein expression (Mantovani et al., 2001).
To address whether this lack of nuclear Dlg in CaSKi and HeLa cells
is indeed due to proteasome mediated degradation of hDlg, we
performed the same experiment, but this time in the presence and
absence of the proteasome inhibitor MG-132 (Figs. 2b–d). As can be
seen, MG-132 treatment results in a similar increase in the level of
hDlg expression in the cytoplasmic fractions of HaCaT and CaSki, as
well as in HeLa cells. In contrast proteasome protection in HaCaT leads
to a similar increase in hDlg levels in both the nuclear and cytoplasmic
fractions whereas in CaSki and HeLa cells there is a proportionately
greater restoration of hDlg levels in the nuclear fraction. It is also
interesting to note that in both cases the protein species rescued in the
nucleus are predominantly the slower migrating forms of the protein
as compared with the cytoplasmic fraction, pointing towards the
rescue of the phosphorylated forms of hDlg. To conﬁrm this, we
repeated the experiment and probed the blots using the phospho-
serine speciﬁc antibodies. As can be seen in Fig. 3a, the anti phospho-
serine 158 antibody recognises hDlg phosphorylated at serine 158
only in the nuclear fraction of proteasome protected CaSki cells. The
results indicate that E6 selectively targets the nuclear fraction of hDlg
phosphorylated on serine 158. In order to provide further support for
this, we performed siRNA knockdown of E6/E7 expression in CaSki
cells and compared the up-regulation of phospho-hDlg with that
obtained using proteasome inhibition in soluble cell extracts. The
results obtained in Fig. 3b show that siRNA knockdown of E6/E7
results in a minimal change in soluble hDlg levels, but that there is a
signiﬁcantly much greater increase in the levels of the phosphorylated
forms of the protein.
Discussion
From these studies we can conclude that it is likely that the E6
oncoprotein targets nuclear phosphorylated hDlg to stop it fromFig. 3. HPV 16 E6 targets the nuclear phosphorylated form of hDlg. (a) CaSki cells were
left untreated or treated with MG-132 and then fractionated into cytoplasmic and
nuclear pools. Dlg was immunoprecipitated using the anti-Dlg mouse monoclonal
antibody and then probed for phospho-serine 158. (b) CaSki cells were transfected
with siLuc, si16E6/E7 or treated with MG-132 prior to harvest. Cell extracts were
immunoprecipitated with anti-Dlg monoclonal antibody and then probed for
phospho-serine 158. The blot was then stripped and re-probed for total immunopre-
cipitated hDlg (polyclonal Dlg). For comparison a parallel western blot was also
performed for p53.performing certain special functions in the cell nucleus. Additionally,
the translocation of hDlg to the nucleus upon phosphorylation by the
CDKs might make it more accessible to the E6 oncoprotein, which has a
largely nuclear localisation, thus improving the efﬁciency of E6-
mediated degradation of the hDlg protein. The question, however,
remains as towhatmight be the possible role of hDlg in the nucleus. The
interaction of the Rho exchange factor Net1 with hDlg promotes its
localisation to nuclear subdomains associated with PML bodies (Garcia-
Mata et al., 2007). The N-terminal deleted oncogenic form of Net1
meanwhile sequesters hDlg in the cytosol, leading to cellular transfor-
mation and providing yet another example of the critical, but as yet
undocumented, role for hDlg in the nucleus. hDlg has also been found to
be expressed in the nuclei of primary keratinocytes in an isoform-
speciﬁc manner (Roberts et al., 2007). In keeping with its role as a
tumour suppressor, hDlg has been shown to behave as a transcriptional
repressor in concertwith p300 (Massimi P., personal communication). It
remains to be seen if this co-operation requires the phosphorylation and
consequent translocation of hDlg to the nucleus. Although this study
sheds light on the putative importance of the nuclear component of
hDlg, the actual role of hDlg in cancer is still a mystery. This is
complicated by the fact that the molecular mechanisms regulating Dlg
function, stability and localisation remain largely unknown. However,
similar to many critical regulators of cellular homeostasis, it seems that
phospho-regulation of Dlg will represent a major aspect of Dlg function.
Materials and methods
Cell culture
HaCaT (Human keratinocyte), CaSki (HPV16 positive cells) and
HeLa (HPV18 cells positive cells) were grown in DMEM supplemented
with 10% fetal bovine serum, penicillin–streptomycin (100 U/ml) and
glutamine (300 μg/ml).
Antibodies
Mouse monoclonal antibody against Dlg (Santa Cruz) (WB 1:500),
polyclonal rabbit anti-α-tubulin (Sigma 1:1000), anti-p84 mouse
monoclonal antibody (Abcam, WB 1:1000), mouse monoclonal
antibody against p53 (Santa Cruz 1:500). Phospho-speciﬁc antibodies
were designed against Serines 158 and 442 on hDlg using the peptide
sequences SHSHI(S)PIKPTE (for serine 158), and LGQTPA(S)PARYSP
(for serine 442), and produced in rabbits by Biosense S.r.l for
Eurogentec Limited, Milano, Italy. They were used at a dilution of
1:1000 inwestern blots. Appropriate secondary antibodies conjugated
to HRP were purchased from DAKO and used for western blotting at a
dilution of 1:2000.
siRNA experiments
CaSki cells were seeded on 10 cm dishes and transfected using
Lipofectamine 2000 (Invitrogen) with control siRNA against luciferase
(siLuc) or siRNA against HPV-16 E6/E7 sequences (Dharmacon). 72 h
after transfection the cells were harvested and soluble cell extracts
(Massimi et al., 2006) analysed by western blotting.
Immunoprecipitation and Western blotting
Cells were lysed in RIPA buffer (50 mM Tris HCl pH 7.4, 1% NP-40,
150 mM NaCl, 1 mM EDTA, plus protease inhibitor cocktail I;
Calbiochem). After incubation on ice for 20 min, lysates were
cleared by centrifugation at 13000 rpm for 10 min. The supernatant
was analysed by SDS-PAGE and Western blotting. For Western
blotting, 0.45 μm nitrocellulose membrane (Schleicher and Schuell)
was used and membranes were blocked for 1 h at 37 °C in 10% milk/
PBS followed by the incubation with the appropriate primary
4 Rapid Communicationantibody diluted in 10% milk/0.5% Tween 20/PBS for 2 h. After
several washes with PBS 0.5% Tween 20, secondary antibodies
conjugated with HRP (DAKO) were diluted in 10% milk/0.5% Tween
20/PBS and incubated for 1 h. Blots were developed using the
Amersham ECL technique according to the manufacturer's instruc-
tions. In the case of Western blotting for phospho-speciﬁc Dlg, the
blots were blocked as mentioned above and then incubated with the
respective phospho-speciﬁc antibodies in 5% BSA/0.5% Tween 20/
PBS, overnight at 4 °C.
Nuclear fractionation assays
Nuclear fractionationwas performed on various cell lines grown to
a 90% conﬂuence on 10 cm dishes. The procedure followed was
according to the manufacturer's instructions, using the NE-PER
Nuclear and Cytoplasmic Extraction Reagents from Pierce Biotechnol-
ogy (# 78833).
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